The effect of palonosetron hydrochloride in the prevention of chemotherapy-induced moderate and severe nausea and vomiting
Authors:
Open Access
- 8 March 2013
- journal article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 5 (5) , 1418-1426
Abstract
The current study aimed to evaluate the efficacy and safety of palonosetron hydrochloride injection for preventing chemotherapy-induced moderate and severe nausea and vomiting. A multi-centered, randomly stratified, double-blind, double-dummy, parallel-group and positive-controlled trial was performed. A total of 240 patients who underwent chemotherapy treatment which induced moderate or severe vomiting were divided into the experimental and control groups. Half an hour before chemotherapy, the experimental group received a 0.25-mg palonosetron hydrochloride injection, whereas the control group received a 3-mg granisetron injection. The acute vomiting complete remission rate (CRR) of the experimental group was not significantly different compared with that of the control group (P=0.35). The delayed vomiting CRR of the experimental group was significantly higher compared with that of the control group (P=0.002). No difference in full course vomiting CRR, vomiting control time, treatment failure time or acute nausea CRR was identified between the two groups. No significant differences in adverse events were observed between the experimental group and the control group. No significant differences in adverse reactions occurred between the experimental group and the control group (12.50%). Palonosetron hydrochloride injection had a better effect on delayed vomiting CRR than granisetron hydrochloride injection. The two injections exhibited similar effects on acute vomiting CRR, full course vomiting CRR, vomiting control time, treatment failure time (days), acute nausea CRR and adverse events.Keywords
This publication has 18 references indexed in Scilit:
- Palonosetron Versus Other 5-HT3 Receptor Antagonists for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer on Chemotherapy in a Hospital Outpatient SettingClinical Therapeutics, 2011
- Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysisSupportive Care in Cancer, 2010
- Randomized Controlled Study Comparing Two Doses of Intravenous Granisetron (1 and 3 mg) for Acute Chemotherapy-induced Nausea and Vomiting in Cancer Patients: A Non-inferiority TrialJapanese Journal of Clinical Oncology, 2009
- A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesisSupportive Care in Cancer, 2007
- Antiemetic efficacy of the neurokinin‐1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high‐dose cisplatinCancer, 2005
- Clinical Science Review: Comparative Review of 5-HT3Receptor Antagonists in the Treatment of Acute Chemotherapy-Induced Nausea and VomitingCancer Investigation, 2000
- Comparative study of the affinities of the 5-HT3 receptor antagonists, YM060, YM114 (KAE-393), granisetron and ondansetron in rat vagus nerve and cerebral cortexNeuropharmacology, 1995
- Pharmacological characterization of RS 25259‐197, a novel and selective 5‐HT3 receptor antagonist, in vivoBritish Journal of Pharmacology, 1995
- The interaction of RS 25259‐197, a potent and selective antagonist, with 5‐HT3 receptors, in vitroBritish Journal of Pharmacology, 1995
- Predictive Factors of Delayed Emesis in Cisplatin-Treated Patients and Antiemetic Activity and Tolerability of Metoclopramide or DexamethasoneAmerican Journal of Clinical Oncology, 1991